BSTC BioSpecifics Technologies Corp

58.73
+1.36  (+2%)
Previous Close 57.37
Open 58.2
Price To Book 3.9
Market Cap 430,511,397
Shares 7,330,349
Volume 46,562
Short Ratio
Av. Daily Volume 61,518

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Endo is currently performing a commercial assessment.
XIAFLEX
Plantar fibromatosis
Phase 2 topline data released June 2016 - endpoints met
XIAFLEX
Human lipomas
BLA filing 2H 2019.
XIAFLEX (collagenase clostridium histolyticum) - RELEASE
Edematous fibrosclerotic panniculopathy (“cellulite”)
Phase 2b trial did not meet endpoint. Endo is currently performing a commercial assessment.
XIAFLEX
Adhesive Capsulitis (“Frozen Shoulder syndrome”)
Phase 1 new data to be presented 2H 2019.
XIAFLEX
Uterine fibroids

Latest News

  1. If You Had Bought BioSpecifics Technologies (NASDAQ:BSTC) Stock Five Years Ago, You Could Pocket A 91% Gain Today
  2. BioSpecifics Technologies (BSTC) Tops Q2 Earnings Estimates
  3. BioSpecifics Technologies Corp. Reports Second Quarter 2019 Financial and Operating Results
  4. Simple Market Timing Strategies That Work - August 05, 2019
  5. BioSpecifics Technologies (BSTC) Earnings Expected to Grow: What to Know Ahead of Q2 Release
  6. Here's Why I Think BioSpecifics Technologies (NASDAQ:BSTC) Might Deserve Your Attention Today
  7. Hedge Funds Have Never Been This Bullish On BioSpecifics Technologies Corp. (BSTC)
  8. BioSpecifics Technologies Corp. Announces Authorization of up to $4 Million Stock Repurchase Program
  9. ImmunoGen Plunges as FDA Recommends New Study for Lead Drug
  10. Catalyst (CPRX) Q1 Loss Narrows, Firdapse Off to a Good Start
  11. Hedge Funds Have Never Been More Bullish On BioSpecifics Technologies Corp. (BSTC)
  12. BioSpecifics: 1Q Earnings Snapshot
  13. Zoetis (ZTS) Earnings Beat Estimates in Q1, Revenues Miss
  14. What's in Store for BioSpecifics (BSTC) This Earnings Season?
  15. Achaogen (AKAO) Files for Bankruptcy, Shares Plunge 65%
  16. Weekly Jobless Claims Lowest in Nearly 50 Years: 5 Top Picks
  17. Zogenix Gets Refusal to File Letter From FDA for Seizure Drug
  18. United Therapeutics Discontinues PAH Drug After Study Fails
  19. 3 Reasons Why BioSpecifics (BSTC) Is a Great Growth Stock